Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Shares Sold by Allspring Global Investments Holdings LLC

Allspring Global Investments Holdings LLC lessened its holdings in shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) by 20.4% during the 4th quarter, Holdings Channel.com reports. The fund owned 15,618 shares of the specialty pharmaceutical company’s stock after selling 4,011 shares during the period. Allspring Global Investments Holdings LLC’s holdings in Jazz Pharmaceuticals were worth $1,933,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also made changes to their positions in the business. UMB Bank n.a. increased its position in Jazz Pharmaceuticals by 70.9% during the fourth quarter. UMB Bank n.a. now owns 311 shares of the specialty pharmaceutical company’s stock worth $38,000 after buying an additional 129 shares during the period. Itau Unibanco Holding S.A. boosted its position in Jazz Pharmaceuticals by 63.2% during the third quarter. Itau Unibanco Holding S.A. now owns 444 shares of the specialty pharmaceutical company’s stock worth $49,000 after purchasing an additional 172 shares in the last quarter. GAMMA Investing LLC raised its holdings in shares of Jazz Pharmaceuticals by 49.8% in the fourth quarter. GAMMA Investing LLC now owns 620 shares of the specialty pharmaceutical company’s stock worth $76,000 after acquiring an additional 206 shares during the last quarter. Venturi Wealth Management LLC raised its holdings in shares of Jazz Pharmaceuticals by 577.0% in the third quarter. Venturi Wealth Management LLC now owns 826 shares of the specialty pharmaceutical company’s stock worth $92,000 after acquiring an additional 704 shares during the last quarter. Finally, Versant Capital Management Inc raised its holdings in shares of Jazz Pharmaceuticals by 56.7% in the fourth quarter. Versant Capital Management Inc now owns 967 shares of the specialty pharmaceutical company’s stock worth $119,000 after acquiring an additional 350 shares during the last quarter. Institutional investors and hedge funds own 89.14% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms have recently weighed in on JAZZ. Robert W. Baird boosted their price target on Jazz Pharmaceuticals from $154.00 to $162.00 and gave the stock an “outperform” rating in a report on Monday, November 18th. Wells Fargo & Company upgraded Jazz Pharmaceuticals from an “equal weight” rating to an “overweight” rating and upped their target price for the company from $130.00 to $170.00 in a research note on Thursday, February 13th. HC Wainwright restated a “buy” rating and set a $200.00 price target on shares of Jazz Pharmaceuticals in a research note on Friday, November 22nd. Morgan Stanley upgraded Jazz Pharmaceuticals from an “equal weight” rating to an “overweight” rating and upped their price target for the stock from $140.00 to $175.00 in a research note on Thursday, December 12th. Finally, Royal Bank of Canada restated an “outperform” rating and set a $179.00 price target on shares of Jazz Pharmaceuticals in a research note on Tuesday, December 10th. One investment analyst has rated the stock with a hold rating, fourteen have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Buy” and an average price target of $180.33.

Insiders Place Their Bets

In other Jazz Pharmaceuticals news, CEO Bruce C. Cozadd sold 1,500 shares of the business’s stock in a transaction dated Thursday, January 2nd. The stock was sold at an average price of $123.43, for a total transaction of $185,145.00. Following the sale, the chief executive officer now owns 425,525 shares in the company, valued at approximately $52,522,550.75. The trade was a 0.35 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Over the last three months, insiders have sold 5,053 shares of company stock worth $617,442. 4.20% of the stock is owned by corporate insiders.

Jazz Pharmaceuticals Price Performance

Shares of Jazz Pharmaceuticals stock opened at $136.01 on Friday. The company has a current ratio of 4.26, a quick ratio of 3.74 and a debt-to-equity ratio of 1.46. The company’s 50-day moving average price is $124.85 and its two-hundred day moving average price is $117.99. Jazz Pharmaceuticals plc has a 52 week low of $99.06 and a 52 week high of $138.27. The stock has a market cap of $8.22 billion, a PE ratio of 19.16, a price-to-earnings-growth ratio of 1.03 and a beta of 0.56.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.